 |
|
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S. E. Keefe, PhD;
Robert M. Bilder, PhD;
Sonia M. Davis, DrPH;
Philip D. Harvey, PhD;
Barton W. Palmer, PhD;
James M. Gold, PhD;
Herbert Y. Meltzer, MD;
Michael F. Green, PhD;
George Capuano, PhD;
T. Scott Stroup, MD, MPH;
Joseph P. McEvoy, MD;
Marvin S. Swartz, MD;
Robert A. Rosenheck, MD;
Diana O. Perkins, MD, MPH;
Clarence E. Davis, PhD;
John K. Hsiao, MD;
Jeffrey A. Lieberman, MD; for the CATIE Investigators and the Neurocognitive Working Group
Arch Gen Psychiatry. 2007;64(6):633-647.
Context Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined.
Objective To compare the neurocognitive effects of several second-generation antipsychotics and a first-generation antipsychotic, perphenazine.
Design Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al. Ziprasidone hydrochloride was included after its approval by the Food and Drug Administration.
Setting Fifty-seven sites participated, including academic sites and treatment mental health facilities representative of the community.
Patients From a cohort of 1460 patients in the treatment study, 817 completed neurocognitive testing immediately prior to randomization and then after 2 months of treatment.
Main Outcome Measures The primary outcome was change in a neurocognitive composite score after 2 months of treatment. Secondary outcomes included neurocognitive composite score change at 6 months and 18 months after continued treatment and changes in neurocognitive domains.
Results At 2 months, treatment resulted in small neurocognitive improvements of z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06), with no significant differences between groups. Results at 6 months were similar. After 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups. Neurocognitive improvement predicted longer time to treatment discontinuation, independently from symptom improvement, in patients treated with quetiapine or ziprasidone.
Conclusions After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition. There were no differences between any pair of agents, including the typical drug perphenazine. These results differ from the majority of previous studies, and the possible reasons are discussed.
Author Affiliations: Departments of Psychiatry and Behavioral Sciences (Drs Keefe, McEvoy, and Swartz) and Biological Psychiatry, John Umstead Hospital (Dr McEvoy), Duke University Medical Center, Durham, NC; Departments of Psychiatry and Biobehavioral Sciences (Drs Bilder and Green) and Psychology (Dr Bilder), University of California, Los Angeles, Neuropsychiatric Institute; Quintiles Inc, Research Triangle Park, NC (Dr Davis); Department of Psychiatry, Mount Sinai School of Medicine, New York, NY (Dr Harvey); Department of Psychiatry, University of California, San Diego (Dr Palmer); Maryland Psychiatric Research Center, Baltimore (Dr Gold); Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn (Dr Meltzer); Department of Psychiatry, School of Medicine (Drs Capuano, Stroup, and Perkins), and Department of Biostatistics (Dr Davis), University of North Carolina at Chapel Hill; Department of Psychiatry, Yale University School of Medicine, New Haven, Conn (Dr Rosenheck); Adult Psychopharmacology Program, Adult Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, Md (Dr Hsiao); and Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York (Dr Lieberman).
RELATED ARTICLE
Cognitive Improvement in Response to Antipsychotic Drugs: Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
R. Walter Heinrichs
Arch Gen Psychiatry. 2007;64(6):631-632.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Measuring Specific, Rather than Generalized, Cognitive Deficits and Maximizing Between-Group Effect Size in Studies of Cognition and Cognitive Change
Silverstein
Schizophr Bull 2008;0:sbn032v1-sbn032.
ABSTRACT
| FULL TEXT
What CATIE Found: Results From the Schizophrenia Trial
Swartz et al.
Psychiatr. Serv. 2008;59:500-506.
ABSTRACT
| FULL TEXT
Lessons to Take Home From CATIE
Carpenter and Buchanan
Psychiatr. Serv. 2008;59:523-525.
ABSTRACT
| FULL TEXT
Implications of CATIE for Mental Health Services Researchers
Covell et al.
Psychiatr. Serv. 2008;59:526-529.
ABSTRACT
| FULL TEXT
Impact of the CATIE Findings on State Mental Health Policy
Parks et al.
Psychiatr. Serv. 2008;59:534-536.
ABSTRACT
| FULL TEXT
Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia
Schmidt et al.
J. Pharmacol. Exp. Ther. 2008;325:681-690.
ABSTRACT
| FULL TEXT
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Parks et al.
Schizophr Bull 2008;0:sbn019v1-sbn019.
ABSTRACT
| FULL TEXT
Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT
| FULL TEXT
CATIE and CUtLASS: can we handle the truth?
Lewis and Lieberman
Br. J. Psychiatry 2008;192:161-163.
ABSTRACT
| FULL TEXT
Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia
Silverstein et al.
Schizophr Bull 2008;0:sbm150v1-sbm150.
ABSTRACT
| FULL TEXT
Bibliography Schizophrenia
Focus 2008;6:197-199.
FULL TEXT
Abstracts
Focus 2008;6:200-204.
FULL TEXT
Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia
Buchanan et al.
Am. J. Psychiatry 2008;165:82-89.
ABSTRACT
| FULL TEXT
Challenge to Atypical Antipsychotic Drug Effect on Cognition
CARPENTER and CONLEY
Am. J. Psychiatry 2007;164:1910-1911.
FULL TEXT
Dr. Keefe and Colleagues Reply
KEEFE et al.
Am. J. Psychiatry 2007;164:1911-1912.
FULL TEXT
The Orexins/Hypocretins and Schizophrenia
Deutch and Bubser
Schizophr Bull 2007;33:1277-1283.
ABSTRACT
| FULL TEXT
Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol
Sergi et al.
Am. J. Psychiatry 2007;164:1585-1592.
ABSTRACT
| FULL TEXT
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect?
Goldberg et al.
Arch Gen Psychiatry 2007;64:1115-1122.
ABSTRACT
| FULL TEXT
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Buchanan et al.
Schizophr Bull 2007;33:1120-1130.
ABSTRACT
| FULL TEXT
Do Antipsychotic Drugs Improve Cognitive Function in Schizophrenia?
JWatch Psychiatry 2007;2007:4-4.
FULL TEXT
Cognition, Drug Treatment, and Functional Outcome in Schizophrenia: A Tale of Two Transitions
Green
Am. J. Psychiatry 2007;164:992-994.
FULL TEXT
Cognitive Improvement in Response to Antipsychotic Drugs: Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Heinrichs
Arch Gen Psychiatry 2007;64:631-632.
FULL TEXT
|
